24 results about "Controlled release drug" patented technology

The invention discloses a method for in vitro slow release performance evaluation of a slow and controlled release preparation based on the overflow principle. A container with an upper outlet and a lower outlet is adopted to serve as a release tank, a to-be-detected medicine and a dissolution medium are placed in the release tank, a stirring device is adopted in the release tank to perform stirring, and the dissolution medium is added from the lower outlet of the release tank through a peristaltic pump; the dissolution medium dissolved with the medicine is taken away through the overflow from the upper outlet so as to offset medicine absorption or metabolism, and the slow and controlled release speed of the medicine, the total medicine overflow quantity and the total release amount are calculated by measuring the concentration of the medicine contained in the dissolution medium flowing out, the volume of the release tank and the overflow quantity. According to the method, the releasing degree of the slow and controlled release medicine can be evaluated accurately, the effective medicine release time of the slow and controlled release preparation is evaluated, and slow release performances of the slow and controlled release preparation are evaluated comprehensively.

This invention provides a method for treating a pulmonary arterial hypertension with reduced incident of side effect using a controlled release pharmaceutical composition of selexipag or its active metabolite, wherein the controlled release pharmaceutical composition of selexipag or its active metabolite following oral administration with an alcoholic beverage reduces incidence of at least one side effect associated with the selexipag or its active metabolite compared to the immediate-release dosage form comprising the same amount of the selexipag or active metabolite thereof.

The invention discloses a soluble microneedle composition for improving sleep and a microneedle and application of the soluble microneedle composition, and belongs to the technical field of medical care, the soluble microneedle composition comprises a needle tip section composition and a substrate composition, comprising 1%-70% of dexmedetomidine or a salt thereof, 1.5%-10% of glycerin, 1.5%-15% of mannitol and the balance of water. The substrate composition is an aqueous solution of a high-molecular compound. The soluble microneedle composition for improving sleep provided by the invention can prevent dexmedetomidine or a salt thereof from diffusing in a microneedle product, so that carried drugs are concentrated at a needle tip part, a technical support is provided for effective transmission of active components and accurate sustained and controlled release drug delivery, and quantitative drug delivery of dexmedetomidine or a salt thereof is realized.

The invention belongs to the technical field of biomedical materials and targeted drug delivery systems, and discloses a targeted controlled-release drug delivery system based on a polymer nano-carrier and a preparation method thereof.The system is of a three-layer structure and comprises a core layer formed by taking polyvinyl alcohol as a matrix and used for efficiently entrapping a drug, and an outer layer formed by taking polyvinyl alcohol as a matrix and used for efficiently entrapping the drug; the shell layer formed by the polylactic acid-glycolic acid copolymer is used for providing structural stability and slow release capability, and the shell layer formed by the polyvinyl alcohol-hydroformylated glucan grafted copolymer is used for realizing microenvironment response release. And the surface of the shell layer is covalently modified with a tumor membrane targeting aptamer and a microenvironment response peptide, so that accurate recognition and local trigger release can be realized. The system has good particle size stability, responsive release ability and tumor cell targeted enrichment effect, and is suitable for efficient delivery and controlled release of various antitumor drugs.

This invention provides a controlled-release pharmaceutical composition containing indigo naturalis or its main active ingredient, a method for its preparation, and its application. The controlled-release pharmaceutical composition comprises microspheres, each microsphere containing the active ingredient and one or more pharmaceutically acceptable excipients. The active ingredient includes indigo naturalis, indigo, indirubin, or any combination thereof; the microspheres are coated with an enteric outer layer. The controlled-release pharmaceutical composition provided by this invention can alleviate the symptoms of inflammatory bowel diseases, especially ulcerative colitis, and can reduce or avoid the endocytosis of the active ingredient by intestinal macrophages, thereby reducing the impact on the patient's liver. It exhibits good stability, and the controlled-release pharmaceutical composition of this invention reduces side effects while maintaining therapeutic efficacy.

The invention provides composite hydrogel, photo-thermal response drug release composite hydrogel as well as a preparation method and application of the photo-thermal response drug release composite hydrogel, and belongs to the technical field of biomedical materials. The hydrogel is constructed by taking methylacryloyl gelatin as a matrix and combining lauric acid microspheres carrying an osteogenesis promoting drug baicalin, a reduced graphene oxide photothermal agent and a photoinitiator LAP. Under the irradiation of near-infrared light, the hydrogel can realize local mild temperature rise, induce the lauric acid microspheres to generate solid-liquid phase change, release the entrapped osteogenesis promoting drug as required, realize the synergistic effect of photothermal therapy and controlled release of the drug, and have a good osteogenesis repair effect. The hydrogel has good mechanical properties, biocompatibility and degradability, can be used for local treatment of bone defect parts, and effectively promotes regeneration and repair of oral and maxillofacial bone tissues. The invention provides a novel controllable and efficient treatment thought for bone tissue engineering and regenerative medicine.

The present disclosure relates to novel radiation-triggered controlled release drug compositions, and methods to make and use the radiation-triggered controlled release drug compositions. The radiation-triggered controlled drug release nanoparticle formulations may be used to achieve maximum bioavailability and minimum adverse effects of the chemo drugs in chemo radio combination therapy treatment of locally advanced solid tumors.

The present invention relates to a controlled release pharmaceutical composition comprising a decongestant, an acrylate copolymer, a cellulose derivative and a crosslinked acrylic acid polymer. The present invention provides an oral dosage form exhibiting a reproducible profile characterized by a controlled release of the decongestant over a period in excess of twelve hours and preferably at least 16 hours after oral administration. The invention further contemplates medical uses thereof. The release profile of the delivery system of the invention is highly reproducible and can be administered once daily, thus improving patient compliance.

The present invention relates to a controlled-release pharmaceutical composition comprising at least a controlled-release pharmaceutical dosage form containing EPAG, the controlled-release pharmaceutical composition being suitable for local injection into an affected area. The present invention also relates to a controlled-release pharmaceutical composition in powder form for preparing the pharmaceutical composition suitable for local injection, and a kit for preparing the pharmaceutical composition comprising an aqueous injection vehicle and a controlled-release dosage form or a mixture of controlled and immediate-release dosage forms containing EPAG, the pharmaceutical composition optionally including an excipient. The composition is useful for local injection in patients to improve stem cell homing and / or treat non-malignant hematological disorders, malignant hematological diseases, primary immunodeficiencies, autoimmune diseases, inborn errors of metabolism, and / or degenerative diseases / injuries.

The present invention provides a controlled-release pharmaceutical composition containing Indigo Naturalis or its main active ingredient, and a preparation method and use thereof. The controlled-release pharmaceutical composition includes micropellets. The micropellets include an active ingredient and one or more pharmaceutically acceptable excipients, the active ingredient includes Indigo Naturalis, indigo, indirubin, or any combination thereof; wherein the micropellets have an enteric outer layer. The controlled-release pharmaceutical composition provided by the present invention can alleviate the disease condition of inflammatory bowel disease, especially ulcerative colitis, and can reduce or avoid the phagocytosis of the active ingredient by intestinal macrophages, thereby reducing the effect on the patient's liver. The composition exhibits good stability and reduces side effects while maintaining therapeutic efficacy.

The invention relates to the technical field of medical instruments, and particularly discloses an intelligent dressing system for chronic wounds. The system comprises a dressing body; a multi-mode sensing array; an edge calculation module; an adaptive intervention actuator; a healing process dynamic evaluation algorithm is built in the edge calculation module; the self-adaptive intervention actuator comprises a micro-pump controlled-release drug reservoir, a flexible heating element and a low-frequency electrical stimulation electrode. According to the system, closed-loop control for monitoring, evaluating and intervening is formed by integrating a healing process dynamic evaluation algorithm and a self-adaptive intervening actuator, an intervening strategy can be automatically adjusted according to the dynamic change of the wound state, instant and personalized nursing guidance is provided for a patient, and real-time dependence on remote medical support is remarkably reduced. A multi-dimensional feature extraction and machine learning classification method adopted by the system improves the objectivity and accuracy of wound state judgment.

The application discloses a controlled-release pharmaceutical composition and a preparation method and application thereof. The controlled-release pharmaceutical composition comprises a quick-release part and an enteric sustained-release part; the quick-release part comprises a first active ingredient, and the enteric sustained-release part comprises a second active ingredient and a sustained-release material; the first active ingredient or the second active ingredient is selected from racemic indobufen or S-indobufen or a pharmaceutically acceptable salt thereof; and the sustained-release material is selected from one or a combination of any number of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, xanthan gum, sodium alginate, sodium carboxymethyl cellulose, acrylic resin, carbomer or polyethylene oxide. The composition can realize once-a-day oral administration, reduces the frequency of drug taking of a patient, and improves the drug taking compliance of the patient; the preparation process is simple, short in time, low in energy consumption, and suitable for industrial production; the influence of food on product burst release is greatly reduced, the stimulation and adverse reactions of the product on the gastrointestinal tract are reduced, and in particular, the risk of gastric hemorrhage is reduced.

Disclosed herein are polymeric implants and controlled release drug delivery systems to provide high drug loading and long-acting drug release. Provided herein are methods for making the same. Methods of administering pharmacologically active agents via the disclosed polymeric implants and controlled release drug delivery systems are also provided.

The application discloses a kind of polydopamine / drug nano composite particles and preparation method and application thereof.The polydopamine / drug nano composite particles in aqueous solution, using the synchronous process of alkaline drug molecule crystallization and dopamine oxidative polymerization, green synthesis nano drug.The polydopamine / drug nano composite particles of the application have: (1) high drug loading efficiency, simple preparation method; (2) have excellent active oxygen scavenging capacity; (3) response active oxygen controlled release drug; (4) the active oxygen of synthesis nano drug retains the activity of drug, such as nanofasudil nano drug can inhibit ROCK signal pathway; (5) good biocompatibility; can significantly reduce the ROS level in diabetic retinopathy model, reduce the expression of inflammatory factors, improve vascular leakage and inhibit neovascularization.The preparation process of the application is simple, the reaction condition is mild, and the biocompatibility is good, which provides a new nano drug delivery strategy for the treatment of diabetic retinopathy.

The embodiments relate to a product comprising a sustained release particle, the sustained release particle comprising a shell and a core, wherein the shell comprises a first material and a second material, wherein the first material is distributed in a matrix of the second material, wherein the first material comprises a nanoparticle that is configured to selectively create holes in the shell by an external stimulus, wherein the second material comprises a first biodegradable material, wherein the core is enclosed by the shell and the core comprises a drug comprising an estradiol-containing drug, wherein the holes allow the drug to be released to an exterior of the shell through the holes.

This invention relates to the synergistic anticancer application of redox-responsive condensates (FFSSFF) for delivering jujube extract and 3-methyladenine. Specifically, this invention relates to the application of redox-responsive condensates in the preparation of targeted drug delivery products, wherein the targeted drug delivery products release drugs in response to glutathione. The active ingredients in the targeted drug delivery products are jujube extract and 3-methyladenine. This invention utilizes an FFSSFF carrier designed based on the LLPS principle, integrating redox-sensitive disulfide bond linkage modules to achieve spatiotemporally controlled drug delivery within a tumor tissue-specific microenvironment with high glutathione concentrations.

The application belongs to the technical field of medical biomaterials, and relates to a controlled-release drug implant, a preparation method thereof and application of the controlled-release drug implant in preparation of a breast cancer postoperative adjuvant therapy drug. A PDLLA solution is collected on a receiver by electrostatic spraying to obtain a PDLLA barrier layer; a PTMC solution containing a first drug active ingredient is collected on the PDLLA barrier layer by electrostatic spinning to obtain a first PTMC drug-loaded layer; a PTMC solution is collected on the first PTMC drug-loaded layer by electrostatic spinning to obtain a PTMC spacer layer; a PTMC solution containing a second drug active ingredient solvent is collected on the PTMC spacer layer by electrostatic spinning to obtain a second PTMC drug-loaded layer, and the controlled-release drug implant is obtained. The application utilizes the drug barrier property of PDLLA and the surface degradation property of PTMC, accurately controls release of doxorubicin and paclitaxel at different time points, and realizes programmed sequential release of the two drugs.

The invention provides a controlled-release drug interventional therapy device adaptive to tumor local drug delivery, and relates to the field of medical instruments. The controlled-release drug interventional therapy device matched with tumor local drug delivery comprises a conveying cylinder, external threads are arranged on the two sides of the outer wall of the conveying cylinder, and the outer walls of the external threads are in threaded connection with positioning screw rings. According to the device, the servo motor provides stable and accurately-regulated driving force, the screw rod is driven to rotate, so that the threaded sleeve rod stably pushes the pressing disc, the rubber abutting block below the pressing disc is in close contact with the piston disc, the medicine pushing deviation caused by incompact contact is avoided, the pressure can be buffered, and the assembly can be protected; the pressing disc pushes the piston disc, the piston rod and the piston to stably move along the inner wall of the conveying cylinder, the moving distance of the piston can be accurately judged in cooperation with assistance of a positioning screw ring and scale marks, then the single-time or continuously-released dosage is accurately calculated and controlled, and the situation that the dosage is insufficient due to the problems of uneven manual operation force, experience judgment deviation and the like is effectively avoided.

The invention provides a long-acting slow-release oral adhesive bandage and a preparation method thereof.According to the preparation method, a three-layer-structure composite film composed of a waterproof layer, a middle film layer and an adhesion layer is obtained in the mode of layer-by-layer coating and drying film forming, and finally the composite film is irradiated to enable cellulose derivatives in the middle film layer to be cross-linked, so that the long-acting slow-release oral adhesive bandage is obtained. The crosslinked cellulose drug-loaded sustained-release layer is obtained, and the long-acting sustained-release oral adhesive bandage is prepared. According to the preparation method disclosed by the invention, a pure physical cross-linking mode is used, and drug coating is realized under the condition that a chemical cross-linking agent is not used; meanwhile, the crosslinked cellulose can also remarkably improve the mechanical property of the product, so that the adhesive bandage has excellent tensile strength; the cross-linked cellulose is degraded into a non-cross-linked state after meeting water, so that the water solubility is increased, and the adhesion time of the adhesive bandage is prolonged. The preparation method disclosed by the invention is simple and easy to operate, and the prepared adhesive bandage has the excellent properties of long adhesion time, high tensile strength, long-acting controlled release of drugs and the like, and is suitable for industrial production.

To provide a novel drug carrier and a drug release controlled preparation using the drug carrier.SOLUTION: A drug carrier according to an embodiment includes an aggregate of cello-oligosaccharides each having, at the anomeric position of a reducing end, a substituent containing an alkyl group. A drug release controlled preparation according to an embodiment includes the drug carrier and a hydrophobic drug.SELECTED DRAWING: Figure 2

The application discloses a temperature-sensitive liposome hydrogel for targeting controllable release of a drug carrier and a preparation method and application thereof, and belongs to the field of liposome hydrogels.The method comprises the following steps: (1) dispersing polysaccharide in water, then adding polyvinyl alcohol, stirring uniformly, and then freezing / thawing the obtained mixed solution for multiple times to obtain a physically cross-linked hydrogel, and then eluting and soaking the hydrogel to obtain the hydrogel; (2) uniformly oscillating a liposome emulsion and the hydrogel, and obtaining the liposome hydrogel through centrifugation and freeze-drying.The application solves the problems that the liposome as a drug carrier is influenced by external environment and temperature conditions, and the targeting characteristics for some diseases are not ideal, and the phenomena of drug leakage and poor effect are caused.The application also realizes the effects of controllable release of a drug and improvement of drug bioavailability, and has a higher drug release amount at a temperature of 42 DEG C.

The present invention relates to a formulation that can inhibit the initial release of a specific PRS inhibitor, and has the effect of preventing side effects of nausea or vomiting that occur when an excessively large amount of the active ingredient is absorbed in the initial stage.

The application discloses a drug release hole position image analysis method and system, and relates to the technical field of image analysis; the method is used for analyzing the drug release hole position of a controlled-release drug device under the irradiation of a light source with a set wavelength and a set polarization degree, and comprises the following steps: collecting a drug release hole position image of the controlled-release drug device in real time, and calculating image statistical features of the drug release hole position image; calculating algorithm parameters for analyzing the drug release hole position image according to the image statistical features and preset rules; analyzing the drug release hole position image according to the algorithm parameters, and outputting an analysis result. The application can collect the drug release hole position image in real time and calculate statistical features of the drug release hole position image, then dynamically adjust algorithm parameters according to the features and preset rules, finally realize accurate analysis of the drug release hole position image, effectively solve the problem that existing technologies cannot accurately analyze the drug release hole position image when the image quality is reduced due to light source aging, and thus improve the accuracy and reliability of detection.